Journal
Medicare and GLP-1s in 2026: The Exclusion, the Indication Doors, and the $50 Bridge
Released: Last reviewed:
The short answer
Medicare's GLP-1 rules are a statute with doors cut in it. The statute: Part D has excluded drugs used "for weight loss" since its 2003 creation — an act-of-Congress problem no plan can waive, though the CMS BALANCE model was designed to add a negotiated-price Part D pathway — and CMS's model page (modified September 29, 2026) now includes an FAQ about "the BALANCE Model not launching in Medicare in 2027." The doors: Part D can and does cover the same molecules for their other FDA indications — Ozempic and Mounjaro for type 2 diabetes (routine), Wegovy for cardiovascular risk reduction (CMS guidance following SELECT opened this in 2024, for beneficiaries with established heart disease), and Zepbound for obstructive sleep apnea (the December 2024 indication) — each requiring the qualifying diagnosis documented, not just present. And the 2026 development: the Medicare GLP-1 Bridge, which since July 1, 2026 has given eligible Part D enrollees a $50 copay and has been extended through December 31, 2027. Per Medicare.gov the Bridge covers Foundayo, Wegovy and the Zepbound KwikPen only, for beneficiaries with a BMI of 35 or more, or 30+ or 27+ with listed conditions; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge (their Part D plan "might cover" a GLP-1). The strategy: if you have one of those diagnoses, file under the indication you qualify for; if you don't, check Bridge eligibility before anything else.
Working the doors, and the cash fallback
The practical sequence for a beneficiary: inventory the qualifying diagnoses (T2D with A1c documentation; prior heart attack, stroke, or peripheral arterial disease for the CV door; a sleep study showing moderate-to-severe OSA for the Zepbound door), have the prescriber code the prior authorization to that indication with the records attached, and expect plan-by-plan formulary variation — Part D plans differ on tiers, PA friction, and preferred agents, which makes the annual enrollment window a real lever for anyone planning treatment. When no door fits and the Bridge's criteria aren't met, the cash board applies with senior-specific notes: the annual math unchanged, the over-65 clinical guide's slower-titration and re-dosing cautions attached, and the manufacturers' direct channels ($149 oral Wegovy through $449 Zepbound vials) as the approved-product lanes. What not to do: pay a platform to "get Medicare to cover Wegovy for weight" — Bridge eligibility can be checked through Medicare.gov and your Part D plan at no cost, outside the Bridge the statute is the statute, and anyone promising coverage beyond those routes is selling the impossible.
Questions people ask
Does Medicare cover Wegovy, Zepbound, or Ozempic?
By indication: Ozempic/Mounjaro for type 2 diabetes (routine Part D coverage), Wegovy for cardiovascular risk reduction (post-SELECT, with established heart disease documented), Zepbound for obstructive sleep apnea (with a qualifying sleep study). Outside those doors, coverage 'for weight loss' remains excluded by statute; the exception is the Medicare GLP-1 Bridge, a $50 copay for eligible Part D enrollees on Foundayo, Wegovy or the Zepbound KwikPen through December 31, 2027.
What is the $50 Medicare GLP-1 pathway?
The Medicare GLP-1 Bridge: since July 1, 2026, eligible Part D enrollees pay a $50 copay, and the Bridge has been extended through December 31, 2027. Per Medicare.gov the Bridge covers Foundayo, Wegovy and the Zepbound KwikPen only, for beneficiaries with a BMI of 35 or more, or 30+ or 27+ with listed conditions; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge (their Part D plan "might cover" a GLP-1). Confirm eligibility with Medicare.gov or your Part D plan before building a budget on it.
What if I'm on Medicare with obesity but no qualifying diagnosis?
Check the Medicare GLP-1 Bridge first: with a BMI of 35 or more (or 30+ or 27+ with listed conditions), eligible Part D enrollees pay $50 for Foundayo, Wegovy or the Zepbound KwikPen through December 31, 2027. Outside the Bridge, the options are the cash channels — $149 oral Wegovy, $349 pens, $299–$449 Zepbound vials, or the verified compounded tier at $99–$179 — with the over-65 clinical cautions (slower titration, medication re-dosing, protein priority) attached.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.